Close Menu
NEW YORK – ERS Genomics said on Tuesday that it has signed a licensing agreement granting Aelian Biotechnology access to its CRISPR-Cas9 patent portfolio to support Aelian's commercial functional genomic screening platform.
 
Aelian, based in Vienna, combines CRISPR-Cas9 screening techniques with single-cell sequencing to identify and investigate disease targets and drug mechanisms of action.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

A federal judge has ruled that drug companies, device manufacturers, and universities need to provide missing clinical data from hundreds of trials to a federal website, ScienceInsider reports.

A genetic analysis suggests red pandas might actually belong to two different species, New Scientist reports.

NPR reports that the US Centers for Disease Control and Prevention has fixed the problem with some of its SARS-CoV-2 testing kits.

In Nature this week: epigenetic factors that prevent healthy aging and more.